KFAS
DFTX

Keating Financial Advisory Services’s Definium Therapeutics DFTX Stock Holding History

Keating Financial Advisory Services’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376 Buy
8
+7
+700% +$173 ﹤0.01% 2380
2026
Q1 		$19 Sell
1
-6
-86% -$102 ﹤0.01% 2512
2025
Q4 		$94 Buy
+7
New +$87 ﹤0.01% 2131

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Keating Financial Advisory Services's DFTX Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Definium Therapeutics (DFTX) stake by 700% in Q2 2026, buying an estimated $173 and bringing the position to 8 shares worth $376. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Keating Financial Advisory Services first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Keating Financial Advisory Services held 8 shares of Definium Therapeutics worth $376 as of Q2 2026.
  • Keating Financial Advisory Services bought 7 Definium Therapeutics shares in Q2 2026, an estimated $173.
  • Definium Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2380 holding.
  • Keating Financial Advisory Services first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.